JBI-589 is a non-covalent PAD4 isoform-selective inhibitor with oral bioavailability. JBI-589 reduces CXCR2 expression and blocks neutrophil chemotaxis. JBI-589 reduces primary tumor and metastases, and enhances the anti-tumor effect of checkpoint inhibitors. JBI-589 can be used in cancer research[1][2].
Molecular Weight:
481.56
Purity:
99.75
CAS Number:
[2308504-22-3]
Formula:
C29H28FN5O
Target:
Protein Arginine Deiminase
Application Notes:
Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
